BNTC - Company ID 0001808898
The table below shows Benitec Biopharma Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $0.00 | $75.00K | $73.00K | $59.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $23.39M | $18.33M | $15.61M | $12.77M | $11.27M | $7.02M |
| SG&A |
Benitec Biopharma Inc. reported annual revenue of $0.00 for fiscal year 2024. That is down 100.0% from $75.00K in fiscal 2023. Over the 6 fiscal years shown, annual revenue declined from $12.20M (FY 2019) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $27.80M |
| $23.43M |
| $6.99M |
| $6.38M |
| $6.65M |
| $6.51M |
| Operating income | -$51.19M | -$41.77M | -$22.49M | -$19.08M | -$17.85M | -$13.60M |
| Income tax | $0.00 | - | - | - | - | - |
| Net income | -$45.67M | -$37.92M | -$21.75M | -$19.56M | -$18.21M | -$13.88M |
| EPS (diluted) | -$0.98 | -$1.05 | -$1.22 | -$14.12 | -$37.88 | -$3.23 |